Assembly Biosciences, Inc. (ASMB): Total Assets
$257.59M
As of 2025-12-31
$330.83M
As of 2026-06-30
+36.3%
3-year compound annual growth
-1.9%
5-year compound annual growth
+6.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $257.59M | +116.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $119.17M | -12.9% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $136.82M | +34.4% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $101.79M | -46.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $191.06M | -32.5% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $283.25M | -16.7% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $339.91M | +26.8% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $268.05M | +58.3% | 2020-03-04, Balance as of period end |
| 2017-12-31 | $169.30M | +72.6% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $98.12M | -26.6% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $133.74M | +87.8% | 2017-03-02, Balance as of period end |
| 2014-12-31 | $71.23M | +162.5% | 2016-03-11, Balance as of period end |
| 2013-12-31 | $27.13M | +32.0% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $20.56M | -44.5% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $37.05M | +153.5% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $14.62M | n/a | 2012-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $257.59M | +116.2% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $717.60M | -25.0% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $899.42M | +21.1% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $1.36B | -0.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $92.11M | +21.0% |
Compare ASMB, BCYC, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗